156 related articles for article (PubMed ID: 28025216)
21. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Gibson CM; Kastelein JJP; Phillips AT; Aylward PE; Yee MK; Tendera M; Nicholls SJ; Pocock S; Goodman SG; Alexander JH; Lincoff AM; Bode C; Duffy D; Heise M; Berman G; Mears SJ; Tricoci P; Deckelbaum LI; Steg PG; Ridker P; Mehran R
Am Heart J; 2021 Jan; 231():121-127. PubMed ID: 33065120
[TBL] [Abstract][Full Text] [Related]
22. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
[TBL] [Abstract][Full Text] [Related]
23. Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C; Moroni G
Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
[TBL] [Abstract][Full Text] [Related]
24. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.
Solomon DH; Garg R; Lu B; Todd DJ; Mercer E; Norton T; Massarotti E
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1246-51. PubMed ID: 24470436
[TBL] [Abstract][Full Text] [Related]
25. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial.
Cercek B; Shah PK; Noc M; Zahger D; Zeymer U; Matetzky S; Maurer G; Mahrer P;
Lancet; 2003 Mar; 361(9360):809-13. PubMed ID: 12642046
[TBL] [Abstract][Full Text] [Related]
26. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.
Hung YM; Wang YH; Lin L; Wang PYP; Chiou JY; Wei JC
Int J Clin Pract; 2018 May; 72(5):e13095. PubMed ID: 29691971
[TBL] [Abstract][Full Text] [Related]
27. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.
Kerr G; Aujero M; Richards J; Sayles H; Davis L; Cannon G; Caplan L; Michaud K; Mikuls T
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1619-26. PubMed ID: 24692402
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine use is associated with reduced mortality risk in older adults with rheumatoid arthritis.
Iyer P; Gao Y; Jalal D; Girotra S; Singh N; Vaughan-Sarrazin M
Clin Rheumatol; 2024 Jan; 43(1):87-94. PubMed ID: 37498463
[TBL] [Abstract][Full Text] [Related]
29. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience.
Das SK; Pareek A; Mathur DS; Wanchu A; Srivastava R; Agarwal GG; Chauhan RS
Curr Med Res Opin; 2007 Sep; 23(9):2227-34. PubMed ID: 17692155
[TBL] [Abstract][Full Text] [Related]
31. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
32. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
33. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
[TBL] [Abstract][Full Text] [Related]
34. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial.
Wasko MC; McClure CK; Kelsey SF; Huber K; Orchard T; Toledo FG
Diabetologia; 2015 Oct; 58(10):2336-43. PubMed ID: 26197707
[TBL] [Abstract][Full Text] [Related]
35. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
[TBL] [Abstract][Full Text] [Related]
36. A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.
de Waha A; Sandner S; von Scheidt M; Boening A; Koch-Buettner K; Hammel D; Hambrecht R; Danner BC; Schöndube FA; Goerlach G; Fischlein T; Schmoeckel M; Oberhoffer M; Schulz R; Walther T; Ziegelhöffer T; Knosalla C; Schönrath F; Beyersdorf F; Siepe M; Attmann T; Misfeld M; Mohr FW; Sievers HH; Joost A; Putman LM; Laufer G; Hamm C; Zeymer U; Kastrati A; Radke PW; Lange R; Cremer J; Schunkert H
Am Heart J; 2016 Sep; 179():69-76. PubMed ID: 27595681
[TBL] [Abstract][Full Text] [Related]
37. Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study.
Hsu CY; Lin YS; Su YJ; Lin HF; Lin MS; Syu YJ; Cheng TT; Yu SF; Chen JF; Chen TH
Rheumatology (Oxford); 2017 Dec; 56(12):2212-2221. PubMed ID: 29029334
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study.
Achuthan S; Ahluwalia J; Shafiq N; Bhalla A; Pareek A; Chandurkar N; Malhotra S
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):174-80. PubMed ID: 25125385
[TBL] [Abstract][Full Text] [Related]
39. Hydroxychloroquine: a multifaceted treatment in lupus.
Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
[TBL] [Abstract][Full Text] [Related]
40. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
